Specifically, NAD rejected Willows argument based on physician prescribing practices, stating that an experts conclusory statement or action is of little value and that expert opinions are most reliable when coupled with competent and reliable evidence demonstrating scientific consensus on an issue. NAD also found that studies referenced by Willow concerning the effectiveness of its products for weight loss only involved FDA-approved GLP-1 products and were insufficient to validate claims for compounded alternatives that differ in active pharmaceutical ingredient, formulation or method of administration. Therefore, NAD concluded that Willow did not establish a reasonable basis for its claims and recommended that Willow discontinue or modify its advertising
Tatarkiewicz K, Sablan EJ, Polizzi CJ, Villescaz C, Parkes DG
What the evidence actually says in 2026: Suicide risk: FDA reviewed the data and on Jan 13, 2026 requested removal of the suicidal ideation warning from GLP-1 labels no increased risk found
Osteoblast number on the surface of trabecular bone was observed by a histological analysis that demonstrated a significant increase after 16 weeks of exendin-4 use in OVX rats ( Glucagon-like peptide-1 promotes the expression of genes related to bone formation
GLP patches are adhesive wellness products marketed for appetite control or weight loss by borrowing the GLP-1 name
Two key players in this hormonal symphony are leptin and ghrelin: the 'satiety' and 'hunger' hormones, respectively
